MAR 31, 2019 08:34 PM PDT

Glowing Tumors Reveal How Immunotherapeutics Work

WRITTEN BY: Nouran Amin

In a study published in the Journal of Clinical Investigation, researchers used positron emission tomography (PET) scans to examine how an immunotherapy drug reaches a tumor and the parts of a cancer that remain unaffected.

Learn more about how PET scans work:

The process of PET imaging uses a synthesized radiolabeled protein that locks on to tumor cells—this allows researchers to visually follow where the so-called checkpoint inhibitor drug binds to a tumor. "This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person," says Sridhar Nimmagadda, Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center.

Radiolabeled protein lights up tumor implanted in the arm of a mouse under a PET scan. The researchers hope to use scans like this one to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected. Credit: Sridhar Nimmagadda via John Hopkins

If PET imaging precision is confirmed to be highly effective in additional tests, it could streamline cancer therapy by enhancing the therapeutic dose of a drug. The use of checkpoint inhibitors is a form of cancer therapy designed to help the immune systems recognize cancer cells and to target them. For example, the programmed death ligand 1 (PD-L1) is one such checkpoint target by three approved therapeutics called atezolizumab, avelumab and durvalumab by the U.S. Food and Drug Administration (FDA).

In the study, researchers created a radiolabeled small protein that binds to PD-L1 which facilitates marking its receptor with a radiotracer seen with PET imaging technique. "In human patients, this could give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly,” says Nimmagadda.

Source: John Hopkins School of Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 10, 2019
Cardiology
DEC 10, 2019
Heart Attacks Without The Risk
Following a heart attack, as the heart heals, scar tissue forms. This issue is less flexible than healthy heart tissue and may encumber the heart's abi...
DEC 10, 2019
Drug Discovery & Development
DEC 10, 2019
Tailor-made Drug for Girl with Rare Genetic Disease
Researchers have used personalized medicine to develop a tailor-made genetic treatment for a girl diagnosed with a rare genetic disease known as Batten dis...
DEC 10, 2019
Drug Discovery & Development
DEC 10, 2019
Psychedelic DMT Creates Vivid Waking Dream State in Brain
In a new study, scientists at Imperial College London investigated how powerful psychedelic dimethyltryptamine (DMT) alters the brain’s electrical ac...
DEC 10, 2019
Drug Discovery & Development
DEC 10, 2019
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
DEC 10, 2019
Drug Discovery & Development
DEC 10, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 10, 2019
Genetics & Genomics
DEC 10, 2019
Finding a Way to Treat Dangerous Protein Aggregates
The scientists are hopeful that this work will lead to new therapeutics for neurodegenerative disease....
Loading Comments...